Everything you need to know about Daratumumab and Multiple Myeloma - Curetalks
Daratumumab for Severe Refractory Proliferative Glomerulonephritis with Monoclonal Immune Deposits (PGNMID). - ATC Abstracts
Current use of monoclonal antibodies in the treatment of multiple myeloma - Varga - 2018 - British Journal of Haematology - Wiley Online Library
False positive results: a challenge for laboratory physicians and hematologists in treating multiple myeloma with daratumumab
SEBIA HYDRASHIFT 2/4 daratumumab test kit | Medical Supply Company
Anti Daratumumab Antibody, clone AbD44786ia | Bio-Rad
How to get clearer test results on monoclonal antibodies
Multiple Myeloma Resources | DARZALEX® (daratumumab) & DARZALEX FASPRO® ( daratumumab and hyaluronidase-fihj) HCP
Electrophoretic patterns post daratumumab - Joanna Sheldon, Rachel D Wheeler, Ray Powles, 2018
Daratumumab - wikidoc
Diagnostics | Free Full-Text | Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
Case 966-- Clinical Chemistry Case
Diagnostics | Free Full-Text | Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study
Double IFE Hydrashift Assay to assess therapy response. During... | Download Scientific Diagram
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma - ScienceDirect
PDF) Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease | Leukemia
Figure 1 from Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA) | Semantic Scholar
DARZALEX® (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis | NEJM
Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay - ScienceDirect
Frontiers | Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
Understanding DARZALEX and DARZALEX FASPRO by International Myeloma Foundation - Issuu
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference
Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials | Scientific Reports
